首页> 外文期刊>Biochimie >Preparation and functional analysis of recombinant protein transduction domain-metallothionein fusion proteins
【24h】

Preparation and functional analysis of recombinant protein transduction domain-metallothionein fusion proteins

机译:重组蛋白转导域-金属硫蛋白融合蛋白的制备及功能分析

获取原文
获取原文并翻译 | 示例
       

摘要

In order for proteins to be used as Pharmaceuticals, delivery technologies need to be developed to overcome biochemical and anatomical barriers to protein drug transport, to protect proteins from systemic degradation, and to target the drug action to specific sites. Protein transduction domains (PTDs) are used for the non-specific transduction of bio-active cargo, such as proteins, genes, and particles, through cellular membranes to overcome biological barriers. Metallothionein (MT) is a low molecular weight intra-cellular protein that consists of 61 amino acids, including 20 cysteine residues, and is over-expressed under stressful conditions. Although MT has the potential to improve the viability of islet cells and cardiomyocytes by inhibiting diabetic-induced apoptosis and by removing reactive oxygen species (ROS), and thereby prevent or reduce diabetes and diabetic complications, all MT applications have been made for gene therapy or under induced over-expression of endogenous MT. To overcome the drawbacks of ineffective intra-cellular MT protein uptake, a human MT gene was cloned and fused with protein transduction domains (PTDs), such as HIV-1 Tat and undeca-arginine, in a bacterial expression vector to produce PTD-MT fusion proteins. The expression and purification of three types of proteins were optimized by adding Zn ions to maintain their stability and functionality mimicking intra-cellular stable conformation of MT as a Zn-MT cluster. The Zn-MT cluster showed better stability than MT in vitro. PTD-MT fusion proteins strongly protected Ins-1 beta cells against oxidative stress and apoptosis induced by glucolipotoxicity with or without hypoxia, and also protected H9c2 cardiomyocytes against hyperglycemia-induced apoptosis with or without hypoxia. PTD-MT recombinant fusion proteins may be useful protein therapeutics for the treatment or prevention of diabetes and diabetes-related complications.
机译:为了将蛋白质用作药物,需要开发输送技术,以克服蛋白质药物运输的生化和解剖学障碍,保护蛋白质免受系统性降解,并将药物作用靶向特定部位。蛋白质转导域(PTD)用于通过细胞膜进行生物活性货物(如蛋白质,基因和颗粒)的非特异性转导,从而克服生物障碍。金属硫蛋白(MT)是一种低分子量细胞内蛋白,由61个氨基酸组成,包括20个半胱氨酸残基,在压力条件下过表达。尽管MT有潜力通过抑制糖尿病引起的凋亡和去除活性氧(ROS)来改善胰岛细胞和心肌细胞的活力,从而预防或减少糖尿病和糖尿病并发症,但所有MT应用都已用于基因治疗或诱导内源性MT过度表达。为了克服无效的细胞内MT蛋白摄取的缺点,在细菌表达载体中克隆了人类MT基因并与蛋白转导域(PTD)(例如HIV-1 Tat和十一碳精氨酸)融合,以生产PTD-MT融合蛋白。通过添加Zn离子以维持其稳定性和功能性来模拟MT作为Zn-MT簇的胞内稳定构象,从而优化了三种蛋白质的表达和纯化。 Zn-MT团簇显示出比MT更好的稳定性。 PTD-MT融合蛋白可强烈保护Ins-1β细胞免受氧化脂质和糖脂毒性诱导的细胞凋亡(无论是否存在缺氧),也可以保护H9c2心肌细胞抵抗高血糖诱导的细胞凋亡(无论是否存在缺氧)。 PTD-MT重组融合蛋白可能是用于治疗或预防糖尿病和糖尿病相关并发症的有用蛋白治疗剂。

著录项

  • 来源
    《Biochimie》 |2010年第8期|P.964-970|共7页
  • 作者单位

    Department of Bioengineering, Institute for Bioengineering and Biopharmaceutical Research, Hanyang University, 17 Haengdang-dong, Seongdong-gu, Seoul 133-791, Republic of Korea;

    rnDepartment of Bioengineering, Institute for Bioengineering and Biopharmaceutical Research, Hanyang University, 17 Haengdang-dong, Seongdong-gu, Seoul 133-791, Republic of Korea;

    rnDepartment of Bioengineering, Institute for Bioengineering and Biopharmaceutical Research, Hanyang University, 17 Haengdang-dong, Seongdong-gu, Seoul 133-791, Republic of Korea Department of Endocrinology, College of Medicine, Hanyang University, 17 Haengdang-dong, Seongdong-gu, Seoul 133-791, Republic of Korea;

    rnDepartment of Bioengineering, Institute for Bioengineering and Biopharmaceutical Research, Hanyang University, 17 Haengdang-dong, Seongdong-gu, Seoul 133-791, Republic of Korea;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    protein transduction domain; metallothionein fusion protein; zn-metallothionein clusters; diabetes and diabetic complication; anti-oxidant and anti-apoptotic agent; hypoxia;

    机译:蛋白质转导结构域;金属硫蛋白融合蛋白;zn-金属硫蛋白簇;糖尿病和糖尿病并发症;抗氧化剂和抗凋亡剂;缺氧;
  • 入库时间 2022-08-18 01:24:02

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号